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Sanofi Pasteur has developed a chimeric yellow fever–dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is cur-
rently approved for use in several countries. In clinical trials, CYD-TDV was efficacious at reducing laboratory-confirmed cases of 
dengue disease. Efficacy varied by dengue virus (DENV) serotype and prevaccination dengue immune status. We compared the 
properties of antibodies in naive and DENV-exposed individuals who received CYD-TDV. We depleted specific populations of 
DENV-reactive antibodies from immune serum samples to estimate the contribution of serotype-cross-reactive and type-specific 
antibodies to neutralization. Subjects with no preexisting immunity to DENV developed neutralizing antibodies to all 4 serotypes of 
DENV. Further analysis demonstrated that DENV4 was mainly neutralized by type-specific antibodies whereas DENV1, DENV2, 
and DENV3 were mainly neutralized by serotype cross-reactive antibodies. When subjects with preexisting immunity to DENV 
were vaccinated, they developed higher levels of neutralizing antibodies than naive subjects who were vaccinated. In preimmune 
subjects, CYD-TDV boosted cross-reactive neutralizing antibodies while maintaining type-specific neutralizing antibodies acquired 
before vaccination. Our results demonstrate that the quality of neutralizing antibodies induced by CYD-TDV varies depending on 
DENV serotype and previous immune status. We discuss the implications of these results for understanding vaccine efficacy.
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Millions of persons living in tropical and subtropical parts of the 
world are infected by dengue viruses (DENVs) each year. Several 
hundred thousand of these infections, especially in children, 
progress to dengue hemorrhagic fever/dengue shock syndrome, 
a life-threatening disease [1]. DENVs belong to the family 
Flaviviridae, which includes other medically significant arbo-
viruses, such as Japanese encephalitis, yellow fever, West Nile, 
tick-borne encephalitis, and Zika viruses. Vaccination is one of 
the most effective strategies for protecting the public from flavi-
virus infections, as demonstrated by the success of yellow fever, 
Japanese encephalitis, and tick-borne encephalitis vaccines.
In the case of dengue, vaccine development is complicated 
by the presence of 4 virus serotypes and the possibility of 
immune-enhanced dengue disease. Nevertheless, many den-
gue vaccines are currently at different stages of development. 
Sanofi Pasteur has developed a chimeric yellow fever–dengue, 
live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is 
currently approved for use in the population aged 9–45 years in 
several countries. In 2 large-scale phase III efficacy trials, CYD-
TDV was efficacious at reducing laboratory-confirmed cases 
of dengue disease, including severe cases and those requiring 
hospitalization [2, 3]. Efficacy varied by serotype, with higher 
efficacy rates against serotypes 3 and 4 than against serotypes 
1 and 2 [2–4]. Furthermore, efficacy was higher in participants 
who had been previously exposed to dengue than in those who 
were dengue naive at baseline [2, 3, 5].
Although the results from live-attenuated dengue vaccine 
trials are encouraging, they also highlight the complexity of 
the human immune response to DENV vaccination, which is 
often not balanced across the 4 serotypes and also influenced 
by prior flavivirus immune status of vaccinees [6, 7]. The goal 
of the current study was to characterize serum from CYD-TDV 
recipients to better understand the specificity and functionality 
of DENV-specific vaccine induced antibodies and to generate 
hypotheses that may explain efficacy data.
DENV envelope (E) protein is the major target of neutraliz-
ing antibody [8]. The crystal structures of the E protein of den-
gue and other flaviviruses have been solved [9–12]. Individual 
subunits of E protein consist of 3 beta-barrel domains desig-
nated domains I, II, and III, with the native protein forming 
Received 14 September 2016; editorial decision 16 November 2016; accepted 21 November 2016; 
published online December 8, 2016.
Correspondence: A. M. de Silva, PhD, 160 Dental Circle, 9004 Burnett Womack,Chapel Hill, 
NC 27599-7292 (aravinda_desilva@med.unc.edu).
The Journal of Infectious Diseases® 2017;125:351–8
© The Author 2016.  DOI:10.1093/infdis/jiw576
a head-to-tail homodimer. The hydrophobic fusion peptide is 
located at the tip of domain II and shielded by domain III of the 
adjacent subunit. A  detailed picture of how E protein dimers 
are organized on the surface of the virion has been obtained by 
combining the crystal structures of E protein with cryo–elec-
tron microscopic reconstructions of the entire virion [13]. Each 
virion has 180 monomers of E protein organized into 90 dimers 
that lie flat on the surface of the virus.
DENVs have epitopes that are unique to each serotype and 
epitopes that are shared between serotypes. Persons who have 
recovered from primary DENV infections develop robust anti-
body responses that cross-react with the 4 serotypes [8, 14]. 
Despite the cross-reactivity, after a limited “grace” period of 
cross-protection, antibodies only prevent reinfection from the 
same serotype (homologous serotype), and individuals are sus-
ceptible to a second infection with a different serotype (heterol-
ogous serotype) [8, 15]. Serotype-specific, strongly neutralizing 
human antibodies have been mapped to different epitopes on E 
protein, including complex quaternary structure epitopes that 
span different E protein molecules [16–23]. Furthermore, recent 
studies indicate that DENV-immune individuals exposed to a 
new serotype develop neutralizing antibodies that bind to sim-
ple and quaternary epitopes that are conserved between sero-
types [15, 19]. Thus, primary DENV infections mainly induce 
neutralizing antibodies that bind to epitopes that are unique to 
the infecting serotype, whereas repeated infections broaden this 
response and induce serotype cross-neutralizing antibodies. 
The cross-protective nature of immunity after repeated infec-
tions may account for the observation that third and fourth 
infections with new serotypes are not as clinically severe as first 
or second infections [24].
Building on results on the specificity and functionality of 
antibodies in persons exposed to natural DENV infections, in 
the current study we compared and contrasted the properties of 
DENV-specific antibodies in naive and dengue-exposed indi-
viduals who were vaccinated with 3 doses of CYD-TDV. Our 
results, which demonstrate differences in the quality of neutral-
izing antibodies depending on virus serotype and prevaccina-
tion immune status, provide a basis for better understanding 
the efficacy data from dengue vaccine trials.
MATERIAL AND METHODS
Clinical Trial Serum Samples
Serum samples from clinical trial subjects naive at baseline 
taken 28  days after the third vaccination of CYD-TDV in a 
0/6/12-month vaccination schedule were used from a study 
conducted in a nonendemic area for dengue (www.clinicaltri-
als.gov NCT01134263) [25]. Serum samples from clinical trial 
subjects preimmune at baseline before initial vaccination and 
28 days after the third vaccination of CYD-TDV in a 0/6/12-
month vaccination schedule were used from a study conducted 
in a dengue-endemic area (NCT01187433) [26]. The serum 
samples tested from this trial were paired prevaccination and 
PD3 samples. Use of clinical trial serum samples for these anal-
yses was performed in accordance with study protocols for 
NCT01134263 and NCT01187433.
Viruses and Cells
WHO reference strains, DENV1 (West Pac 74), DENV2 
(S-16803), DENV3 (CH-53489) and DENV4 (TVP-376) were 
used in the present study unless otherwise noted. The strains were 
grown in C6/36 mosquito cells to generate infectious stocks and 
Vero-81 mammalian cells to generate purified antigen. DENVs 
from culture medium were purified by means of density gradi-
ent and ultracentrifugation, as described elsewhere [27]. DENV2 
purified antigen was purchased from Microbix Biosystems.
Whole-Virus Depletion of DENV-Specific Antibodies From Vaccine 
Immune Serum Samples
Purified DENV was adsorbed onto 4.5-μm Polybead poly-
styrene microspheres (Polysciences; catalog No. 17135-5) at 
a bead (microliter) to ligand (microgram) ratio of 5:2. Beads 
were washed 3 times with 0.1  mol/L Borate buffer (pH 8.5), 
followed by an overnight incubation with purified DENV and 
0.1  mol/L Borate buffer (8.5) at room temperature. Control 
beads were incubated with the equivalent amount of bovine 
serum albumin. The control and virus-coated beads were then 
blocked 3 times with a 10 mg/mL bovine serum albumin solu-
tion for 30 minutes at room temperature, followed by 4 washes 
with 0.1 mol/L borate buffer (pH 8.5) and then 4 washes with 
×1 phosphate-buffered saline. DENV-specific antibodies were 
depleted from human serum samples by incubating virus-ad-
sorbed beads with human serum samples diluted 1:10 in 
phosphate-buffered saline for 45 minutes at 37°C 3 times with 
end-over-end mixing. Successful depletion of DENV-specific 
antibodies was confirmed via enzyme-linked immunosorbent 
assay (ELISA), in which the plates are coated with the same 
DENV antigen used for depletion.
ELISA Methods
Initial titration ELISA is done on the serum samples, in which 
the ELISA plate is coated with the DENV antigen with which 
the serum will be depleted. The initial ELISA helps quantify the 
amount of DENV antigen needed to fully deplete the serum from 
the respective serotype. After depletion, confirmation ELISA 
was performed to confirm that the serum was fully depleted 
from all antibodies that could bind to the serotype of depletion.
Neutralization Assays
Neutralizing titers were initially measured through the standard 
DENV plaque reduction neutralization assay (PRNT) [28] In the 
present study, we used a flow cytometry–based assay that uses a 
human monocytic cell line (U937) expressing dendritic cell-spe-
cific intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN), which generates neutralization titers qualitatively 
similar to those of PRNT [29]. Briefly, DENV depleted and 
control depleted serum samples are incubated with each of the 
4 DENV serotypes separately for 45 minutes at 37°C. Cells are 
then added and incubated for 2 hours at 37°C. After 2 hours the 
cells are washed with medium and incubated for 24 hours at 
37°C. After 24 hours the cells are fixed and permeabilized. The 
percentage of infection is measured by staining the cells with 
2H2, a preMembrane (prM) protein specific mouse monoclonal 
antibody, conjugated to Alexa488 fluorophore using flow cytom-
etry. Using the 50% neutralization antibody titers (Neut50), the 
percentage of cross-reactive (CR) and type-specific (TS) neutral-
izing antibodies against each serotype were calculated as follows:
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RESULTS
Flavivirus-Naive Subjects Vaccinated With CYD-TDV
We first analyzed blood samples collected from 11 subjects 
who had no evidence of exposure to dengue before vaccina-
tion (Supplementary Table  1). To measure levels of DENV 
neutralizing antibodies induced by vaccination, we used a flow 
cytometry–based assay that uses a human monocytic cell line 
(U937) expressing DC-SIGN. Figure  1 and Supplementary 
Table  1 depicts the 50% neutralizing antibody titers against 
each of the 4 serotypes in these 11 subjects. Although there 
was considerable variability among subjects in the levels of 
neutralizing antibodies to the different serotypes, the mean 
levels to serotypes 2 and 4 were higher than those to serotypes 
1 and 3.
Persons exposed to primary DENV infections develop 
serotype-specific neutralizing antibodies [16]. After repeated 
DENV infections with different serotypes, individuals main-
tain both serotype-specific and cross-reactive neutralizing 
antibodies. We performed experiments to estimate levels of 
type-specific and cross-reactive neutralizing antibodies in naive 
subjects who had received 3 doses of CYD-TDV. Polystyrene 
beads coated with purified DENV antigen were used to selec-
tively remove serum antibodies that bound to a particular 
serotype (Figure  2A). Antibody depletion was confirmed by 
ELISA before performing DENV neutralization assays with the 
4 serotypes. A serotype-specific (homotypic) response was the 
fraction of neutralizing antibodies against a particular serotype 
that remained after depletion with antigen from heterologous 
serotypes. For example, as depicted in Figure 2B, when a sample 
from subject 1 was depleted with DENV2 antigen, ELISA con-
firmed loss of DENV2 binding antibodies. When the depleted 
sample was used in a neutralization assay with the 4 serotypes, 
we observed a large loss of DENV2, a partial of loss of DENV1 
and DENV3, and no loss of DENV4 neutralization (Figure 2C). 
These results indicate that DENV4 is mainly neutralized by 
type-specific antibodies, whereas a mixture of type-specific and 
cross-reactive antibodies neutralize DENV1 and 3. The data are 
inconclusive about the properties of DENV2 neutralizing anti-
bodies, because both DENV2 type-specific and cross-reactive 
antibodies have been depleted from the sample. To determine 
the quality of DENV2 neutralizing antibodies, the sample was 
separately depleted using beads coated with DENV4 antigen 
(Figure 2D and 2E). The DENV4 depletion resulted in a large 
loss of DENV2 neutralization, demonstrating that cross-re-
active antibodies dominated the DENV2 response. Using this 
approach, we estimated levels of homotypic neutralizing anti-
bodies in all 11 naive subjects who were vaccinated. As depicted 
in Figure 3, the DENV4 response was dominated by type-spe-
cific neutralizing antibodies, whereas DENV1, DENV2, and 
DENV3 responses had lower levels of type-specific neutralizing 
antibody. This pattern of type-specific antibodies dominating 
the DENV4 response was observed when we analyzed an addi-
tional 14 flavivirus-naive subjects who had received 3 doses of 
CYD-TDV (Supplementary Figure 1).
Flavivirus-Preimmune Subjects Vaccinated With CYD-TDV
To evaluate the antibody response among dengue-exposed 
individuals who were vaccinated with CYD-TDV, we analyzed 
blood from 7 subjects who were recruited in a dengue-endemic 
region. Blood samples collected 1 month after the final vaccine 
dose were analyzed using the same approaches described for 





















Figure 1. Neutralizing antibody levels in chimeric yellow fever–dengue, live-at-
tenuated, tetravalent dengue vaccine (CYD-TDV) recipients who were dengue virus 
(DENV) naive before vaccination. Neutralizing antibodies were measured in sam-
ples collected from 11 subjects 1 month after the final vaccine dose. Each data point 
represents the 50% neutralization antibody titer (Neut50) for a single subject for the 
specified serotype; horizontal bars represent geometric mean titers.
subjects had varying levels of neutralizing antibodies to DENV 
serotypes consistent with prior exposure to primary or repeated 
DENV infections (Figure  4A and Supplementary Table  2). 
The overall levels of neutralizing antibodies to all 4 serotypes 
increased when preimmune subjects were vaccinated with 
CYD-TDV (Figure 4A and Supplementary Table 2). Moreover, 
Figure 3. Proportion and level of homotypic neutralizing antibodies to each serotype in dengue virus (DENV)–naive subjects who received the chimeric yellow fever–den-
gue, live-attenuated, tetravalent dengue vaccine (CYD-TDV). The antibody depletion assay was used to measure proportions of DENV type-specific (homotypic) neutralizing 
antibodies induced by CYD-TDV in DENV-naive subjects. A, Each data point represents the percentage of the total neutralizing antibody response to the specified serotype 
attributed to type-specific antibodies; horizontal bars represent geometric mean titers. Two-way analysis of variance (ANOVA) was used to calculate P values (DENV4 vs 
DENV1, P = .003; DENV4 vs DENV2, P < .001; DENV4 vs DENV3, P = .005). B, Each data point represents the absolute level of homotypic neutralizing antibody to the specified 
serotype (50% neutralization antibody titer [Neut50]); horizontal bars represent geometric mean titers. Two-way ANOVA was used to calculate P values (DENV4 vs DENV1, 
P = .001; DENV4 vs DENV2, P = .006; DENV4 vs DENV3, P = .004).
Figure 2. Dengue virus (DENV) antibody depletion assay to estimate proportions of serotype-specific and cross-reactive neutralizing antibodies in serum samples from 
chimeric yellow fever–dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) recipients. A, Schematic of the antibody depletion method. Serum is incubated with 
polystyrene beads coated with purified DENV2 or DENV4 virions. A negative control depletion is performed using beads coated with bovine serum albumin. The virus-coated 
beads (or control beads) were pelleted, and the supernatant was collected for further analysis. B–E, Antibody depletion and DENV neutralization results for CYD-TDV subject 
1. Abbreviations: NHS, normal human serum; OD, optical density. B, D, Enzyme-linked immunosorbent assay was used to confirm removal of DENV2 or DENV4 binding anti-
bodies. C, E, DENV neutralization assays were performed with the DENV2 or DENV4 antibody-depleted samples to estimate proportions of type-specific and cross-reactive 
neutralizing antibodies against each of the 4 DENV serotypes.
preimmune subjects attained higher levels of neutralizing anti-
bodies than naive subjects who were vaccinated, with the excep-
tion of DENV4, for which both groups had similar titers after 
vaccination (Figure 4B).
We next performed antibody depletions to determine 
whether CYD-TDV induced type-specific or cross-reactive 
neutralizing antibodies in preimmune subjects. As depicted 
in Figure 5A, the vaccine mainly induced cross-reactive neu-
tralizing antibodies in preimmune individuals. This pattern is 
clear when persons with primary DENV2, DENV3, or mult-
itypic responses are analyzed as separate groups (Figure 5B–
5D). The single subject categorized as having had a past 
DENV2 primary infection had high levels of DENV2-specific 
neutralizing antibodies at enrollment (Figure 5B). After vac-
cination, this subject developed high levels of neutralizing 
antibodies to all 4 serotypes, which were mainly cross-reac-
tive antibodies. A  similar pattern of cross-reactive antibody 
boosting was also observed for subjects who had evidence 
of past primary DENV3 infection (Figure  5C) or multitypic 
immunity (Figure  5D). It is also important to note that in 
nearly all cases preexisting type-specific neutralizing antibod-
ies were maintained after vaccination, and in some cases the 
vaccine actually boosted preexisting type-specific responses 
to DENV3.
DISCUSSION
As exemplified by the yellow fever 17D vaccine developed >75 
years ago, live virus vaccines can be very effective against fla-
viviruses. Several live DENV vaccines are in clinical trials and 
the leading product developed by Sanofi (CYD-TDV) has been 
licensed in several countries. In clinical trials, CYD-TDV effi-
cacy varied by serotype and efficacy was higher in participants 
who had been previously exposed to dengue than in those who 
were dengue naive when vaccinated [2, 3, 5]. In CYD-TDV 
efficacy trials, while the mere presence of DENV neutralizing 
antibodies was not correlated with protection [4], vaccine effi-
cacy curve models have now identified a correlation between 
PRNT50 titers and efficacy [30]. However, although high titers 
were a remarkably consistent signature of high vaccine effi-
cacy, other factors besides Neut50 titers may play a role when 
considering lower titers. Therefore, beyond quantitative levels, 
it is important to explore additional qualitative aspects of the 
immune response.
The goal of the current study was then to characterize 
serum from CYD-TDV recipients to clarify the specificity 
and functionality of DENV-specific vaccine-induced anti-
bodies and to generate hypotheses that may explain vaccine 
efficacy data. DENV-naive subjects who received 3 doses of 
CYD-TDV developed neutralizing antibodies to each of the 
4 DENV serotypes. DENV serotypes 1, 2, and 3 were mainly 
neutralized by cross-reactive antibodies, whereas sero-
type-specific antibodies were mainly responsible for DENV4 
neutralization.
In naive subjects, why did CYD-TDV mainly induce 
type-specific neutralizing antibodies to DENV4 but not to 
DENV1, DENV2, and DENV3? Previous studies have demon-
strated that the DENV4 component in CYD-TDV replicates 
to higher titers in animals and in persons compared with the 
other 3 serotypes [6]. The superior replication of DENV4 is 
most likely responsible for the type-specific responses to this 
serotype, whereas the cross-reactive neutralizing antibod-
ies against the other 3 serotypes could result to a significant 
degree from unbalanced vaccine virus replication. However, 
some persons did develop substantial levels of type-specific 
responses against DENV1, DENV2, and DENV3, suggesting 
that these vaccine components replicated well in some indi-
viduals. This exemplifies expected variability from individual 
to individual, also seen in the level of neutralization achieved 
across a given population [2].
CYD-TDV efficacy was lower in naive subjects even though 
the vaccine induced neutralizing antibodies to all 4 serotypes 
in the PRNT50 assay, albeit at different levels [4, 30]. In fact 
early clinical studies with CYD-TDV demonstrated lower rep-
lication and antibody responses to DENV1 and 2 components 
Figure 4. Neutralizing antibody levels in chimeric yellow fever–dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) recipients who were dengue virus (DENV) 
preimmune when vaccinated. A, DENV neutralizing antibody levels in DENV-preimmune subjects vaccinated with CYD-TDV. Serum samples from 7 DENV-preimmune subjects 
at base line were tested at day 0 before CYD-TDV administration. Samples from the same subjects were tested 1 month after the final dose. Each data point represents the 
50% neutralization antibody titer (Neut50) for a single subject for the specified serotype; horizontal bars represent geometric mean titers. B, Comparison of DENV neutralizing 
antibody levels induced by CYD-TDV in naive and preimmune subjects. Each data point represents the Neut50 for a single subject for the specified serotype; horizontal bars 
depict geometric mean titers.
compared with DENV4 [31, 32]. In persons exposed to nat-
ural primary DENV infections, serotype-specific antibodies 
have been linked to long-protective immunity [15]. Tertiary 
quaternary structure antibody epitopes displayed on the sur-
face of intact dengue virions are the main targets of neutral-
izing antibodies in persons exposed to natural infections [16, 
33]. Induction of these antibodies are likely to be dependent 
on active viral replication and stimulation of naive B cells by 
intact virus particles. Although natural primary infections can 
also stimulate cross-reactive antibodies with measurable neu-
tralizing activity in cell culture, these antibodies do not seem 
to provide durable cross-protection from other serotypes. We 
propose that in dengue-naive subjects who are vaccinated, the 
levels of type-specific antibodies that target complex epitopes 
displayed on the viral surface are likely to contribute signifi-
cantly to vaccine efficacy. This hypothesis is testable using data 
and samples from the recently completed CYD-TDV 14 and 15 
efficacy trials.
CYD-TDV performed particularly well in persons with 
preexisting immunity to DENV. Our data demonstrate that in 
dengue-immune subjects, CYD-TDV induced high levels of 
cross-reactive antibodies that broadly cross-neutralized DENV 
serotypes. Persons exposed to natural second DENV infections 
also develop broadly cross-reactive neutralizing antibodies. In 
fact, the cross-protective nature of second infection–induced 
antibodies may explain why third DENV infections are mild 
or clinically unapparent [24]. We propose that the superior 
efficacy of CYD-TDV in DENV-preimmune individuals is 
mediated by the induction of cross-reactive and cross-pro-
tective antibodies that are similar to antibodies induced after 
natural second DENV infections. Recent studies have identi-
fied complex E protein interdimer epitopes on the viral surface 
targeted by serotype cross-neutralizing antibodies produced by 
plasmablasts in persons exposed to repeated DENV infections 
[18]. Studies are ongoing to determine whether the cross-re-
active neutralizing antibodies induced by the CYD-TDV in 
preimmune subjects target E protein interdimer or related epi-
topes. Our results are consistent with the hypothesis proposed 
by Guy and Jackson [34] that CYD-TDV may act as a pri-
mary infection in those who are seronegative and a secondary 
Figure 5. Levels of homotypic and heterotypic dengue virus (DENV) neutralizing antibodies (Abs) induced by chimeric yellow fever–dengue, live-attenuated, tetravalent 
dengue vaccine (CYD-TDV) in preimmune subjects. A, Proportions of DENV homotypic neutralizing antibodies induced by vaccine. The antibody depletion assay was used to 
measure proportions of DENV type-specific (homotypic) neutralizing antibodies induced by CYD-TDV in DENV-preimmune subjects. Each data point represents the percent-
age of the total neutralizing antibody response to a serotype attributed to type-specific antibodies; horizontal bars represent geometric mean titers. B–D, Absolute levels 
of type-specific DENV neutralizing antibodies before and after vaccination with CYD-TDV. The antibody depletion assay was used to measure absolute levels of DENV 
type-specific (homotypic) and cross-reactive (heterotypic) neutralizing antibodies induced by CYD-TDV. Homotypic antibody is shown in solid black; heterotypic antibody, in 
stripes. Bars represents the total 50% neutralization antibody titer (Neut50) for each serotype. Neutralizing antibody levels in subjects with evidence of prevaccination DENV2 
exposure (B), DENV3 exposure (C, left to right), and secondary exposure (D, left to right) are depicted as separate graphs.
infection in those who are seropositive—with different impacts 
on vaccine efficacy.
It is important to note that in preimmune individuals, CYD-
TDV induced broadly cross-reactive neutralizing antibodies, 
while maintaining, and in some cases enhancing, preexisting 
type-specific responses. In our small subset of DENV-primed 
individuals, several subjects had type-specific responses to 
DENV2 or DENV3 indicative of previous exposure to these 
serotypes. These type-specific responses were maintained even 
after receipt of CYD-TDV and in the case of DENV3, the vac-
cine enhanced DENV3 type-specific responses. We propose 
that CYD-TDV can stimulate both cross-reactive and type-spe-
cific memory B cells, depending on the replication of individual 
vaccine components in preimmune subjects.
The main limitation of our study is that we were able to ana-
lyze only a relatively small number of samples because of the 
complex and laborious nature of antibody depletion studies. For 
DENV-naive subjects, we first analyzed 11 subjects and then an 
additional 14 subjects and observed a clear trend wherein the 
DENV serotype 4 neutralizing antibody response was type spe-
cific, whereas the responses for serotypes 1, 2, and 3 were mainly 
due to cross-reactive antibodies. For the preimmune population, 
we analyzed 7 subjects and observed a large increase in serotype 
cross-reactive neutralizing antibodies. Although CYD-TDV con-
tinues to be evaluated in short- and long-term clinical trials, 2 
other companies have also recently launched large phase III tri-
als with different live dengue vaccines. The results we report here 
provide a foundation for analyzing vaccine data and samples and 
establishing correlates and mechanisms of protective immunity.
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